Compare CRSP & AUGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | AUGO |
|---|---|---|
| Founded | 2013 | 1946 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.8B |
| IPO Year | 2016 | 2009 |
| Metric | CRSP | AUGO |
|---|---|---|
| Price | $55.44 | $78.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 10 |
| Target Price | $87.56 | ★ $101.91 |
| AVG Volume (30 Days) | ★ 1.3M | 895.4K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,063.30 | $69.92 |
| Revenue Next Year | $283.48 | $20.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $29.11 |
| 52 Week High | $78.48 | $110.32 |
| Indicator | CRSP | AUGO |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 41.97 |
| Support Level | $50.56 | $71.04 |
| Resistance Level | $60.04 | $91.28 |
| Average True Range (ATR) | 2.83 | 3.66 |
| MACD | -0.03 | -1.72 |
| Stochastic Oscillator | 51.06 | 6.06 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.